tamoxifen

(redirected from 4-hydroxytamoxifen)
Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

tamoxifen

 [tah-mok´sĭ-fen]
a nonsteroidal oral antiestrogen used as the citrate salt in the treatment and prophylaxis of breast cancer.

tamoxifen

/ta·mox·i·fen/ (tah-mok´sĭ-fen) a nonsteroidal antiestrogen used as the citrate salt in the prophylaxis and treatment of breast cancer.

tamoxifen

(tə-mŏk′sə-fĕn)
n.
A drug that is a selective estrogen receptor modulator, C26H29NOS, used in the form of its citrate primarily to treat breast cancer in women whose tumors are estrogen-dependent and to prevent breast cancer in high-risk women.

tamoxifen

[təmok′səfin]
a nonsteroidal antiestrogen used in the palliative treatment of advanced breast cancer in premenopausal and postmenopausal women whose tumors are estrogen dependent. Tamoxifen has also been used to reduce the incidence of breast cancer in women with a high risk for developing it and for treating gynecomastia, precocious puberty, and other instances of estrogen excess.

tamoxifen

Adjuvant tamoxifen, Novaldex® Oncology A nonsteroidal anti-estrogenic used to treat early estrogen receptor–ER-positive breast CA; prophylactic tamoxifen may used in postmenopausal ♀ at high risk for breast CA Other benefits ↓ Serum lipids, ↓ risk of CAD; it maintains bone mass and ↓ osteoporosis Cons ↑ risk of endometrial CA. See Breast cancer, Chemokine, STAR. Cf Raloxifene.

tamoxifen

A drug that blocks oestrogen receptors and is useful in the treatment of certain cancers, especially breast cancer. Research involving 37,000 women has shown that tamoxifen substantially improves the survival figures after breast cancer and substantially reduces the probability of cancer in the other breast. The drug also stimulates egg production from the ovaries and can be used to treat infertility. It is on the WHO official list. Brand names are Nolvadex and Tamofen.

tamoxifen

hormone antagonist used to treat/prevent breast cancer; patients on tamoxifen are prone to thromboembolism, especially postsurgery or following prolonged rest

tamoxifen

an antiestrogen used as the citrate in the treatment of disseminated mammary cancer.

Patient discussion about tamoxifen

Q. Hot flashes while on tamoxifen - is there anything to do? Hello, Last year I was diagnosed with breast cancer, and after surgery and radiation, I was given tamoxifene. In the beginning it was OK, but now I have hot flashes. Usually I can to hold my self until It passes, but some times (like during work) it’s just so bothering- is there anything I can do to make these flashes go?

A. Just a short update, I took Riki's advice and went to see my doctor a couple of days ago - now I just have to wait and see if the medicine he gave me will do the trick.

Q. I heard about tamoxifen. Should women who have an increased risk of breast cancer take tamoxifen?

A. Dear Elizabeth, women with an increased risk of breast cancer can think about taking tamoxifen to reduce their risk. As with any medical procedure or treatment, the decision to take tamoxifen is a personal one in which the benefits and risks must be discussed with your doctor. The balance of these benefits and risks will vary depending on a woman's personal health history and how much importance she puts on the benefits and risks. Even if a woman has an increased risk of breast cancer, tamoxifen therapy may not be right for her. Any woman who is thinking about tamoxifen therapy should talk with her doctor about her personal health situation to make the best decision.

Q. Want to know how this tamoxifen works to fight cancer as my lump is removed and is there any side effects? Hi… I am 26 years lady, my breast cancer lump is removed and after my chemo I am on tamoxifen now……wanted to know how this tamoxifen works to fight cancer as my lump is removed now and is there any side effects associated with it?

A. With, Tamoxifen uterine cancer risk is there to some. As Breast cancers have estrogen receptors which stimulate the cancer cell to grow and tamoxifen inhibits. If post surgery you have any incidence of cancer reversal due to estrogen then tamoxifen will inhibit and will complete your treatment.

More discussions about tamoxifen
References in periodicals archive ?
In addition, isomerization of 4-hydroxytamoxifen is catalyzed by CYP1B1,2B6, and 2C19 (7).
O-glucuronidation of 4-hydroxytamoxifen is mainly mediated by UDP-glucuronosyltransferases (UGTs) UGT1A4, 2B15, 2B7, 1A8, and various others to produce 4-hydroxytamoxifen-O-glucuronide (33-35).
We possess a genetic "switch" that controls expression of telomerase, but, unlike the mice that were altered to respond to 4-hydroxytamoxifen, we don't know exactly what chemical turns telomerase on in our bodies.
At steady state, achieved after 2 weeks of therapy, mean plasma 4-hydroxytamoxifen levels were just 1/18 of those measured in 19 healthy controls taking 20 mg/day of oral tamoxifen.
TamoGel(TM) is a percutaneously applied gel formulation of the anti-estrogen 4-hydroxytamoxifen (4-OHT), the most active metabolite of tamoxifen.
17[beta]-Estradiol, genistein and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein-coupled receptor GPR30.
TamoGel(TM) is a percutaneously applied gel formulation of 4-Hydroxytamoxifen (4- OHT) that is currently under investigation in a variety of benign and malignant estrogen-dependent conditions by ASCEND Therapeutics.
Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells.